Loomis, Sayles & Company
TTPH

Loomis, Sayles & Company’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Loomis, Sayles & Company’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,993
Closed -$17.1M – 1085
2015
Q2 		$17.1M Buy
+17,993
New +$14.7M 0.05% 372

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Loomis, Sayles & Company's TTPH Position: Q3 2015 in Review

Loomis, Sayles & Company sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2015, closing a stake of 17,993 shares — an estimated $17.1M sold.

Loomis, Sayles & Company first reported a position in TTPH in Q2 2015 and held it in 1 quarter. The position peaked at $17.1M in Q2 2015. 105 funds tracked by Wall St. Rank hold TTPH as of Q3 2015.

  • Loomis, Sayles & Company reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Loomis, Sayles & Company sold 17,993 Tetraphase Pharmaceuticals, Inc. shares in Q3 2015, an estimated $17.1M.
  • Loomis, Sayles & Company first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Loomis, Sayles & Company's Tetraphase Pharmaceuticals, Inc. position peaked at $17.1M in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2015.

Based on Loomis, Sayles & Company's 13F filing for Q3 2015, filed 13 Nov 2015.